# Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct07552181/  
OnCo record `nct07552181` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by Yuan Yuan, not yet recruiting.

## Summary

Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT07552181 by Yuan Yuan, with a registry enrolment figure of 50 participants, started 2026-09 and due to reach its primary completion in 2035-09. Interventions recorded: Live biotherapeutic product: MO-03 1 capsule PO BID. Conditions listed: TNBC - Triple-Negative Breast Cancer; TNBC; Early Stage Triple-Negative Breast Carcinoma. Triple-negative eligibility wording from the registry: "* Patients with high-risk early stage triple negative breast cancer". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07552181
- Phase: 2
- Setting: Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer
- Sponsor: Yuan Yuan
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT07552181: https://clinicaltrials.gov/study/NCT07552181

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07552181.json